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Purpose: There is currently no adequate method of mapping
physiologic and pathophysiologic tissue albumin concentra-
tions in human subjects. The objective of this study was to
devise and evaluate a biomarker of regional albumin concen-
tration using gadofosveset-enhanced MRI.
Theory and Methods: A binding and relaxation model was
devised and evaluated in vitro in solutions of albumin at 3.0
Tesla (T) and 4.7T. The method was evaluated in the heart in
seven volunteers at 3.0T.
Results: MRI-derived estimates of albumin concentration were
in good agreement with true values over the range 0.1–1.0 mM
(Pearson correlation coefficients of 0.85 and 0.88 for 3.0T and
4.7T, respectively). The mean calculated albumin concentration
in the myocardium for the volunteers was 0.02 mM (range, 0.01–
0.03 mM).
Conclusion: Accurate estimates of albumin concentration in
vitro suggest this may be a viable noninvasive alternative to
existing techniques. In the myocardium the MRI-derived esti-
mates of albumin concentration indicate the practical feasibil-
ity of the technique but were below expected values.
Gadofosveset-enhanced MR relaxometry has potential in pro-
viding biomarkers of regional albumin concentration; further
evaluation is required before it can be used reliably in vivo.
Magn Reson Med 73:244–253, 2015. VC 2014 University of
Leeds. Magnetic Resonance in Medicine published by
Wiley Periodicals, Inc. This is an open access article under
the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
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INTRODUCTION
Albumin is the most abundant protein in human plasma,
accounting for half of all serum proteins (1). It transports,
by means of its numerous binding sites, endogenous com-
pounds (2) and drugs (3), and is essential in regulating the
flow of water between blood and tissue (1). Around 33% of
albumin in the body is intravascular, with 49% in
exchangeable extravascular locations and the remainder in
remote extravascular compartments such as the skin (4). An
imbalance in intra–extravascular albumin may potentially
result in edema. Albumin concentrations may be accurately
measured in urine or blood samples, with altered levels
caused by changes in rates of synthesis, catabolism or
extravascular leakage. Low levels of albumin have been
linked to critical illness (5) and may be a risk factor for
myocardial infarction (6). The body’s natural transcapillary
exchange rate of around 5% of intravascular albumin per
hour (7) may increase in damaged or angiogenic vessels.
Localized increases in extravascular macromolecular con-
tent may be symptomatic of, for example, reperfused myo-
cardial infarction (8) or tumor angiogenesis (9).
Although albumin concentrations in blood and urine
are valuable indicators of albumin imbalance, they do not
fully describe its biodistribution. Direct measurement of
interstitial albumin concentration is not straightforward,
with varying results found using invasive techniques such
as wick implantation (10), blister suction (11) or double
lumen catheterization (12). It is suggested that a noninva-
sive biomarker (13) of localized extravascular albumin
may facilitate quantitative assessment of extravascular
leakage. This may have prognostic and/or diagnostic value
in assessment of tumor angiogenesis or myocardial infarc-
tion, for example, and may also be used for prospective
assessment of response to treatment. Although conven-
tional small-molecule gadolinium (Gd) contrast agents are
frequently used in MRI to assess microvascular permeabil-
ity, macromolecular Gd agents have shown increased sen-
sitivity to malignancy (14), response to anti-angiogenic
treatment (15) and ischemic microvascular damage (16).
Gadofosveset trisodium (Ablavar, Lantheus Medical
Imaging, N Billerica, MA, previously marketed as Vasov-
ist, Schering AG, Germany) is a Gd-containing contrast
agent, with a stable gadopentetate core and phosphodies-
ter linkage to a lipophilic albumin-binding group (17). In
humans, over 90% of injected gadofosveset is reported to
bind reversibly to serum albumin (18), increasing the
effective molecular weight of the contrast agent from 957
Da to 68 kDa (19). Binding alters the pharmacokinetics of
the molecule, reducing its extravasation and excretion
rates; consequently the agent is well suited to angiography
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(20). Beyond angiography, recent studies have utilized
gadofosveset in assessment of human brain tumors (21),
liver lesions (22), chronic myocardial infarction (23), ath-
erosclerosis (24), and liver fibrosis (25), and in combina-
tion with spin locking in vitro (26).
Substantially higher longitudinal and transverse relaxiv-
ities are observed for gadofosveset at low magnetic field
strengths upon binding (27), due to the lower tumbling
rate and longer correlation time of the bound molecule
(28). The longitudinal and transverse relaxivities of the
free (unbound) molecule are slightly higher than those of
a conventional (nonbinding) small-molecule Gd-based
agent such as gadopentetate (29). At physiologically appli-
cable concentrations, it may be assumed that one gadofos-
veset molecule binds to a single albumin molecule
(18,30). In this case, the bound fraction of gadofosveset is
at a maximum where albumin exceeds gadofosveset con-
centration and declines where gadofosveset exceeds albu-
min concentration. This relationship suggests that, under
certain conditions, it may be possible to use gadofosveset
binding fraction as a biomarker for albumin concentration.
However, signal intensity changes induced by the bound
and free gadofosveset molecules cannot be directly sepa-
rated in vivo and therefore binding fraction must be
acquired through mathematical modeling.
This study aims to assess the viability of utilizing meas-
ured gadofosveset-enhanced longitudinal (R1, 1/T1) and
transverse (R2, 1/T2) relaxation rates to develop a biomarker
of albumin concentration in vitro. This method could be
applied to generate a spatially located measure of tissue
albumin which could be used as an alternative to current
invasive techniques. Model feasibility is assessed using R1
and R2 measurements in vitro and in left ventricular blood
and myocardial tissue of healthy human volunteers at 3.0
Tesla (T). Identification of abnormal extravascular albumin
distribution correlating to increased capillary leakage may
have several applications, including early indication of dis-
ease progression or treatment response in tumor angiogene-
sis, or assessment of reperfused myocardial infarction.
THEORY
Measuring Albumin Binding Fraction
For conventional Gd-based contrast agents, a single lon-
gitudinal relaxivity (r1) is usually sufficient to describe
the relationship between the contrast-agent induced
change in R1 (DR1) and gadofosveset concentration (Cg);
likewise a single transverse relaxivity (r2) describes the
relationship between DR2 and Cg:
DRi ¼ ri:Cg [1]
where i¼ 1,2.
For albumin-binding gadofosveset, composite relaxivities
are observed, comprising contributions from both the bound
and free molecule. For the B0 field strengths used in this
study, relaxivity of the bound molecule exceeds that of the
free molecule. For the free molecule, the relationship in Eq.
[1] may be assumed. For the bound molecule, there is a
nonlinear relationship between Cg and R1,2 (although at
high field r1bound approaches r1free and the relationship
between Cg and R1 tends to linearity). The overall gadofos-
veset and serum albumin (Csa) concentrations may be
defined as the sum of their bound and free components:
Cg ¼ Cgbound þ Cgfree [2]
Csa ¼ Csabound þ Csafree [3]
At low B0 field strengths, the distinct relaxivities of
the bound and free gadofosveset molecules must be
considered:
DR1 ¼ r1bound:Cgbound þ r1free:Cgfree [4]
DR2 ¼ r2bound:Cgbound þ r2free:Cgfree [5]
Assuming DR1 and DR2 can be measured and r1bound,
r1free, r2bound, and r2free are known, it is possible to rear-
range Eqs. [4] and [5] to give expressions for bound and
free gadofosveset concentration:
Cgbound ¼ r2free:DR1  r1free:DR2
r1bound:r2free  r2bound:r1free [6]
Cgfree ¼ r1bound:DR2  r2bound:DR1
r1bound:r2free  r2bound:r1free [7]
Combining Eqs. [6] and [7] according to Eq. [2] gives:
Cg ¼ DR2 r1bound  r1freeð Þ  DR1 r2bound  r2freeð Þ
r1bound:r2free  r1free:r2bound [8]
Bound, free, and overall gadofosveset concentrations can
therefore be derived from measurement of DR1 and DR2.
Measuring Albumin Concentration
In a second step, gadofosveset concentration is related to
albumin concentration by assuming a chemical equilib-
rium between free and bound substances. The noncova-
lent binding equilibrium between a paramagnetic
substrate and a protein is defined as (31):
Substrate½  þ Protein½ ½Substrate–Protein
The association constant, or binding affinity (Ka),
involving a single equivalent binding site may be
expressed as (31):
Ka ¼ ½Substrate–Protein
Substrate½ :½Protein :
Expressing this binding affinity in terms of gadofosve-
set and albumin concentrations:
Ka ¼
Cgbound
Cgfree:Csafree
[9]
Assuming a single bound gadofosveset molecule per
serum albumin molecule:
Cgbound ¼ Csabound [10]
Eq. [9] becomes:
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Ka ¼
Cgbound
Cgfree: Csa  Cgbound
  : [11]
Rearranging for Csa:
Csa ¼ Cgbound þ 1
Ka
:
Cgbound
Cgfree
[12]
Inserting Eqs. [6] and [7] into Eq. [12] gives:
Csa ¼ r2free:DR1  r1free:DR2
r1bound:r2free  r2bound:r1free
þ 1
Ka
:
r2free:DR1  r1free:DR2
r1bound:DR2  r2bound:DR1 : [13]
Eq. [13], therefore, provides a method for deriving
albumin concentration through measurement of DR1 and
DR2, assuming fixed relaxivity and binding affinity
values.
Measuring Bound Relaxivity
It remains to derive a method for measuring the relaxiv-
ity values from in vitro samples with known gadofosve-
set concentrations. Free relaxivity is derived using Eq.
[1], applied to a solution without albumin. To derive a
formula for bound relaxivity, Cgfree is first eliminated
from Eq. [11] using Eq. [2], and the quadratic equation
solved for Cgbound. Inserting the result into Eq. [4] or Eq.
[5] gives an expression for DR1 or DR2 where only bound
relaxivity is unknown:
DRi ¼ rifree:Cg þ ribound  rifreeð Þ:
Csa:Ka þ Cg :Ka þ 1
   Csa:Ka þ Cg :Ka þ 1
 2  4:Ka2:Csa:Cg
h i
2:Ka
8<
:
9=
;
[14]
where i¼ 1,2.
Only the negative form of the quadratic solution is
applicable as the positive form would give a nonzero
solution for Cgbound at Cg¼ 0. Eq. [14] has been repre-
sented in a similar form in several papers (for example,
(30,32,33)). The model describes a gradual transition of
binding fraction, from a maximum at low Cg, where
observed relaxivity is dominated by r1,2bound, toward a
minimum at high Cg, where r1,2free has the greater influ-
ence (Fig. 1). As the model assumes a single binding
site, the shift in emphasis from r1,2bound to r1,2free occurs
at around Cg¼Csa.
Accepting that r2bound> r2free, it follows from Eq. [2]
and Eq. [5] that, in all cases:
DR2 < r2bound:Cg [15]
It should be noted that experimental imprecision in R2
measurement (and R1 measurement, as Cg is calculated
using Eq. [8]) may violate this inequality, and may lead
to calculated values of Csa 0 mM. For transverse relax-
ivity, r2bound is much higher than r2free at all B0 values;
for longitudinal relaxivity, r1bound is much higher than
r1free at low B0 but both are effectively equivalent at very
high B0 (34). This variation with field strength means
that at low B0 any imprecision in R2 measurement has a
much greater influence on calculated Cg (Eq. [8]), there-
fore, it is expected that the model may not be applicable
at low B0 values.
METHODS
In Vitro Validation
Model validation was carried out by calculating Csa
(using Eq. [13]) for a range of in vitro solutions. This
requires values of Ka, DR1, DR2, r2bound, r2free, r1bound, and
r1free. DR1 and DR2 were measured within the study, a
fixed Ka value of 11.0 mM
1 was assumed in calcula-
tions (27,28,32), and relaxivity values were derived from
the data presented in this study (as values for matching
experimental conditions could not be found in the
literature).
In vitro solutions of gadofosveset (Vasovist) were pre-
pared for use at 3.0T with phosphate-buffered saline
(PBS, dry powder reconstituted with deionized water,
pH 7.4, Sigma Aldrich, St Louis, MO) and human serum
albumin (HSA, Cohn fraction V lyophilized powder,
Sigma Aldrich, in PBS). Solutions were created at Csa
and Cg concentrations between 0 and 1.0 mM; a total of
26 combinations of gadofosveset and HSA were pre-
pared. A set of solutions containing the nonbinding con-
trast agent gadopentetate dimeglumine (Magnevist, Bayer
Healthcare Pharmaceuticals, Germany) in HSA at
Csa¼ 0.7 mM were created to act as a control. The solu-
tions measured at 4.7T used bovine serum albumin
(BSA, Cohn fraction V lyophilized powder, Sigma
Aldrich, in PBS) in place of HSA, within the same range
of concentrations.
r1free and r2free were calculated by applying the linear
model in Eq. [1] to the DR1 and DR2 values for the gadofos-
veset–PBS samples (Csa¼ 0 mM), where no binding was
assumed. To prevent the relaxation rates for any given
FIG. 1. Modeled variation of DR2 with gadofosveset concentration
for three serum albumin concentrations, based on Eq. [14],
assuming values of Ka¼11.0 mM1, r2bound¼60.0 s1 mM1,
r2free¼6.1 s1 mM1 (29)
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gadofosveset–albumin sample(Csa> 0 mM) influencing
the relaxivity values subsequently used to calculate Csa
for that sample, bound relaxivity was calculated by set-
ting aside one sample and applying a one-parameter
model fit to the remaining subset of DR1 and DR2 values
(using Eq. [14]). This process was repeated for each sam-
ple until a set of individual r1bound and r2bound values was
created. The calculated relaxivities associated with each
excluded sample (and its measured DR1 and DR2 values)
were used in the subsequent Csa calculation for that sam-
ple using Eq. [13].
In Vitro Data Acquisition: 3.0T
Tubes were placed vertically within a cardiac coil in a
3.0T Philips Achieva TX system. Solutions were main-
tained at a temperature of 34–37C with warm air flow,
verified with a fiber optic temperature probe in an adja-
cent water tube. T1 values were measured using a spin
echo inversion recovery sequence with 5 inversion times
(TI¼ 50, 225, 371, 1665, 4875 ms), repetition time
(TR)¼ 5000 ms, echo time (TE)¼6.2 ms. T2 values were
measured using a multi-echo sequence with eight echo
times (TE¼ 50, 100, 150, 200, 250, 300, 350, 400 ms),
TR¼ 1000 ms. Additional parameters common to both T1
and T2 measurement: field of view¼231  231 mm;
matrix size¼240  240 pixels; single coronal (horizon-
tal) slice; slice thickness¼ 10 mm.
In Vitro Data Acquisition: 4.7T
Tubes were placed vertically in a cylindrical cradle of
diameter 60 mm and inserted into a 63-mm quad coil in
a horizontal bore 4.7T magnet with Bruker console run-
ning ParaVision 5.1 software (Bruker BioSpin MRI
GmbH, Ettlingen, Germany). Solutions were maintained
at a temperature of 37C with warm air flow, verified
with a fiber optic temperature probe in an adjacent water
tube. R1 values were measured using a RARE saturation
recovery imaging sequence (35), with nine recovery
times (57.2, 68.5, 78.5, 88.5, 103.5, 183.5, 283.5, 383.5,
983.5 ms) and a TE of 11 ms. R2 values were measured
using a multi-slice multi-echo (MSME) sequence, with
20 equally spaced TE values from 11 to 220 ms and a TR
of 1000 ms. Additional parameters common to both T1
and T2 measurement: field of view¼ 60  60 mm; matrix
size¼ 256  256 pixels; RARE factor¼2; averages¼ 1;
centric encoding; single coronal (horizontal) slice; slice
thickness¼1 mm.
Relaxation Rates
A circular region of interest (ROI) was drawn within
each tube and the mean signal intensity (SI) of each ROI
measured using ImageJ software (v1.42q, Rasband, W.S.,
ImageJ, U. S. National Institutes of Health, Bethesda,
MD, http://imagej.nih.gov/ij/, 1997–2011). SI values at
4.7T were adjusted for noise bias using a simple Rician
correction (36), based on mean standard deviations of
four background regions in each image. R1 values at 4.7T
and R2 values at 3.0T and 4.7T, along with 95% confi-
dence intervals, were determined from two-parameter
nonlinear fits to Eqs. [16] and [17], respectively, using
MATLAB (v 7.9, MathWorks, Natick, MA). R1 calculation
at 3.0T included an extra term for TR (Eq. 18).
SI ¼ S0: 1 eTI :R1
 
[16]
SI ¼ S0:eTE:R2 [17]
SI ¼ S0: 1 b:eTI :R1 þ eTR:R1
 
[18]
where S0 represents the fully recovered SI value and b is
a factor accounting for imprecision in the 180 inversion
pulse, applied to each ROI.
Contrast agent-induced changes in relaxation rate
(DR1,2) were calculated by subtracting R1,2 values for
each non-Gd Csa solution (Cg¼ 0) from equivalent Gd-
containing Csa solutions (Cg> 0).
In Vivo Feasibility Assessment: 3.0T
A total of seven healthy volunteers (five male, mean age
36610 years, mean weight 816 15 kg) underwent pre-
and postcontrast short-axis cardiac scans on a 3.0T Sie-
mens Skyra system at Northwestern Memorial Hospital,
Chicago. The study was approved by the Institutional
Review Board (IRB) at Northwestern University, with
informed consent obtained from all participants. IRB
approval did not include provision for taking blood sam-
ples, therefore per-volunteer measures of hematocrit and
blood albumin were not available.
Images were acquired as part of a larger study mapping
flow patterns in thoracic aortic aneurisms (TAA) in dif-
ferent progression stages. Myocardial T1 and T2 values
with administration of an MR contrast agent were also
acquired to study changes of these parameters associated
with inflammatory and connective tissue diseases that
are in turn associated with the progression of TAA. A
small timing bolus of 1.0–2.0 ml of gadofosveset (Abla-
var) was used to establish arrival time and was followed
by a main bolus of 6.2–8.8 mL, giving a total dose of
0.12 mL/kg (0.03 mmol/kg). A modified Look-Locker
inversion recovery (MOLLI) sequence (37) with motion
correction (38) (field of view¼ 270  360 mm, matrix
size¼ 144  256 pixels, flip angle¼ 35, TR¼ 313.45 ms,
TE¼ 1.13 ms, bandwidth/pixel¼ 975 Hz) was used for
T1, with T1 maps created inline by the system software.
This version of the MOLLI sequence consisted of two
inversions, with three images acquired after the first
inversion (initial effective TI of 120 ms, and RR interval
added to the other two acquisitions), and five images
acquired after the second inversion (first effective TI of
200 ms; 200 msþRR for subsequent acquisitions).
Images were acquired with a specific trigger delay to
select for end diastole. MOLLI acquisition was followed
by a T2 mapping sequence using a single-shot T2-pre-
pared steady-state free precession (SSFP) acquisition
with three T2-preparation echo times: 0, 24, and 55 ms
(39) (field of view¼ 337  450 mm, matrix size¼ 144 
192 pixels, TR¼ 201.88 ms, TE¼ 1.07 ms, flip
angle¼ 40, bandwidth/pixel¼ 930 Hz). For all sequen-
ces, 8 mm slices were acquired at cardiac short axis
base, mid and apex locations. Postcontrast images were
acquired at up to three time points for each volunteer,
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with T2 image acquisition occurring 1–2 min after T1
acquisition (Table 1). The mid-point between T1 and
T2 image acquisitions was used as the postcontrast ref-
erence time for each data point when plotting the
results.
ROIs were drawn within the left ventricle and within
the myocardium on each pre- and postcontrast T1 and
T2 map at the middle of the short axis view, and median
and standard deviation values derived using MATLAB.
For albumin calculation, each ROI is considered as a
single well-mixed compartment, which is a valid
assumption for the left ventricle, where gadofosveset is
entirely intravascular, but is a simplification of condi-
tions in the myocardium, where DR1 and DR2 are influ-
enced by gadofosveset in vascular and extravascular
spaces.
As the described T2 acquisition protocol is optimized
for myocardial T2 measurement it is likely to underesti-
mate the longer T2 of native blood, which may lead to an
underestimation in DR2 calculation. To investigate this
influence, an underestimation in DR2 was simulated and
the effect on calculated albumin values observed.
Expected DR2 values were obtained using Eq. [14] across
a range of Csa and Cg values, based on derived in vitro
3.0T relaxivities; these DR2 values were then reduced by
an arbitrary 10% and Csa values calculated according to
Eq. [13].
RESULTS
In Vitro Data at 3.0T and 4.7T
Mean individual gadofosveset relaxivity values measured
at 3.0T and 4.7T for the range of Csa–Cg combinations are
given in Table 2; standard deviations indicate the var-
iance in calculated relaxivity.
Figure 2 shows model fits (Eq. [14]) plotted against
actual DR1 and DR2 gadofosveset data points at 3.0T and
4.7T, using the mean individual relaxivities in Table 2.
A linear fit to the gadopentetate data is also shown.
In Figure 3 calculated Csa values (using Eq. [13]) are
compared with actual values for each solution using
individually derived relaxivity values at 3.0T and 4.7T.
Four data points violated the inequality described in
Eq. [15], and were therefore excluded from the 4.7T cal-
culations. The model-derived Csa values correlate with
actual Csa at a statistically significant level at both field
strengths (Pearson correlation coefficients of 0.85 and
0.88 for 3.0T and 4.7T, respectively).
Volunteer Data at 3.0T
Precontrast T1 values in the left ventricle and myocar-
dium were in the range 1493–1818 ms and 1099–1124 ms,
respectively. Precontrast T2 values in the left ventricle
and myocardium were in the range 117–158 ms and 43–
47 ms, respectively. Calculated gadofosveset and albumin
concentrations in the left ventricle and myocardium are
shown in Figure 4, with data for all seven volunteers plot-
ted against time from first bolus administration. The mod-
els for calculating gadofosveset (Eq. [8]) and albumin
(Eq. [13]) concentrations used the 3.0T (PBS/HSA) relax-
ivity values shown in Table 2.
The effect of an underestimation in DR2 on calculated
Csa was simulated at a range of Cg values, using the 3.0T
relaxivity values from Table 2. Simulations showed that
a 10% underestimation in DR2 led to an underestimation
in calculated Csa. This model underestimation increases
as actual Csa increases, and is more pronounced at lower
Cg. For example, at Csa¼1.0 mM calculated Csa is 0.6
mM lower than actual Csa for Cg ¼0.1 mM, but calculated
Csa is only 0.2 mM lower than actual Csa for Cg¼ 1.0
mM.
DISCUSSION
Increased capillary leakage is symptomatic of a range of
pathologies and healthy processes, resulting in rapid
wash-in and wash-out of small molecule contrast agents
and an increased transfer of macromolecules, including
intravascular albumin, to the interstitial space. In vivo
measurement of extravascular albumin content is not
straightforward, although a range of invasive techniques
are currently available. This study has explored the pos-
sibility of utilizing the albumin-binding properties of the
Table 1
Main Bolus and Image Acquisition Times for Volunteersa
Volunteer no. Main bolus
Measurement
T1 [1] T2 [1] T1 [2] T2 [2] T1 [3] T2 [3]
1 07:08 14:31 16:47 – – – –
2 03:52 08:57 11:19 38:34 39:35 54:06 55:53
3 02:35 07:10 08:10 29:12 30:15 – –
4 04:15 29:17 31:44 – – – –
5 08:24 41:43 43:25 – – – –
6 03:24 23:45 25:02 28:09 29:29 39:23 40:38
7 03:06 05:34 07:21 18:34 20:16 27:02 28:36
aTime from first administration of contrast agent (timing bolus), MM:SS.
Table 2
Mean Individual Gadofosveset Relaxivity Values (and SDs)
3.0T 4.7T
Relaxivity
(s1 mM1)
This study
(PBS/HSA) Literaturea
This study
(PBS/BSA) Literaturea
r1bound 10.0 (0.1) 9.9 6.5 (0.0) 6.9
r1free 6.1 (0.3) 5.3 4.5 (0.1) 5.5
r2bound 100.9 (0.7) 60.0 60.0 (0.2) 60.0
r2free 7.5 (0.2) 6.1 10.7 (0.2) 6.9
aLiterature values from (29), where r1,2free are measured in water
at 37C and r1,2bound are observed relaxivities in bovine plasma at
37C.
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Gd-based contrast agent gadofosveset to generate a novel
and location-specific noninvasive method for measuring
levels of albumin at moderate to high magnetic field
strengths. Pre- and postcontrast R1 and R2 measurements
are regularly carried out in MRI; the models presented
here combine these changes in relaxation rate with
FIG. 2. DR1 (left column) and DR2 (right column) values for gadofosveset at a range of albumin concentrations and for gadopentetate at
0.7 mM, at 3.0T (upper row) and 4.7T (lower row). Points represent measured values (with 95% confidence intervals); gadofosveset lines
represent model fit based on relaxivities in Table 2; gadopentetate lines represent linear fit.
FIG. 3. Bland–Altman plots of actual versus difference (calculated – actual) Csa at 3.0T (26 plotted points) (a) and 4.7T (24 plotted points)
(b). Dashed lines indicate standard deviation of difference
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calculated relaxivity values and a literature binding
affinity value to produce a basic measure of tissue albu-
min concentration.
In Vitro Model Validation
Calculated r1 and r2 relaxivity values at both 3.0T and
4.7T are in general agreement with previously published
values (Table 2), although it is difficult to find directly
equivalent experimental conditions for comparison.
Using mean calculated relaxivity values, the model rep-
resents a good fit to gadofosveset DR1 and DR2 data
points at low and high Csa values (Fig. 2), suggesting that
the assumption of a single binding site on the albumin
molecule is adequate at these concentration levels. The
primary binding site is known to provide the greatest
contribution to relaxivity (28), and it is unlikely that Cg
levels would be sufficiently high in vivo during the post-
bolus phase to necessitate inclusion of additional bind-
ing sites in this model (32). An attempt to model the
data with second and third binding sites filled sequen-
tially according to relative Cg and Csa concentrations,
using binding affinity values of 0.84 and 0.26 mM1
(28), did not noticeably alter the model fits to measured
data points (data not shown).
Excluding negative calculated Csa values resulting
from measurement imprecision and comparing the
remaining calculated and actual Csa values (Fig. 3), the
model-derived Csa values correlate with actual Csa at a
statistically significant level at both 3.0T and 4.7T.
The albumin-calculation model presented here is
expected to work well at higher B0 field strengths (3.0T
and above), where there is a large difference between
r2bound and r2free but a small difference between r1bound
and r1free. At low fields, r1bound is close to r2bound and the
difference between DR1 and DR2 is small. In this case,
the precision of the model input parameters would be
insufficient to overcome the sensitivity of the model to
the variability in those parameters, leading to a break-
down of the model. At very high B0 field strengths,
r1bound and r1free values for gadofosveset may be consid-
ered equivalent and the model may be simplified to
incorporate a linear relationship between DR1 and Cg.
The Cg calculation described in Eq. [8] may then be rep-
resented as Cg¼DR1/r1.
An underlying correlation between relaxivity and pro-
tein content has been shown in previous studies for Gd-
based contrast agents not conventionally described as
albumin binding (40,41). In vitro gadopentetate DR2 data
points are well represented here by a linear fit (Fig. 2),
suggesting no observable influence of weak binding on
contrast agent relaxivity at the albumin levels used in
this study. Without separate bound and free transverse
relaxivities, gadopentetate provides no means of estimat-
ing Csa through application of the model presented here.
The high binding affinity of gadofosveset makes it a
much more sensitive biomarker of albumin.
In Vivo Feasibility
Gadofosveset-enhanced cardiovascular imaging is an area
of active research (42–46), and likely to remain so in
North America where the agent is available under the
trade name Ablavar. One potential clinical application of
the technique for calculating albumin concentration
relates to myocardial infarction, therefore a feasibility
assessment using human cardiac images was considered
relevant. Cardiac imaging has the advantage of enabling
direct comparison of calculated albumin values from
blood in the left ventricle and from highly perfused myo-
cardial tissue. However, before the model can be
assessed, motion correction and other technical chal-
lenges must be overcome.
Precontrast T1 and T2 values generally correlate well
with literature values (47–49), although longer T2 values
in blood have been quoted elsewhere (50). Combining
FIG. 4. Calculated gadofosveset (a) and albumin (b) concentrations in myocardium (open symbols) and left ventricle (filled symbols) in
healthy volunteers at 3.0T. Each symbol shape represents a different volunteer; values are plotted against time from first administration
of contrast agent (to mid-point between T1 and T2 image acquisition times); error bars indicate uncertainty in calculations, calculated by
propagation of errors using standard deviation of initial R1 and R2 ROI measurements (errors are symmetrical about data point, but only
one side shown to aid clarity)
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data from seven volunteers with images acquired at a
range of time points gave remarkably consistent values of
the two model input variables DR1 and DR2, and sup-
ported calculation of appropriate Cg values in both the
left ventricle and the myocardium (Fig. 4a). As expected,
gadofosveset concentration peaks at the earliest time
points postbolus and decreases toward an equilibrium
value, although this was not a dynamic acquisition
therefore the temporal resolution is such that the bolus
peak is not fully described.
At a dose of 0.03 mmol per kg, the average blood con-
centration of gadofosveset for an 81 kg adult with a total
blood volume of 6.4 L would be 0.4 mM; allowing for
some extravasation and excretion, the gadofosveset val-
ues calculated here in the left ventricle appear reasona-
ble. For a small molecule agent such as gadopentetate,
approximately 50% may diffuse to the extravascular
space from the blood on the first pass through the capil-
lary bed (51). Although, as a “blood pool” agent, gadofos-
veset may be expected to remain predominantly within
the intravascular space, at high concentrations (immedi-
ately after bolus injection, for example) the bound frac-
tion will be low and the extravasation rate may be
similar to that of a conventional agent (52). A study in
rabbits showed that 61% of injected gadofosveset was
still in the blood at 1 min postinjection (32). Certainly, a
reduction in Cg between the left ventricle and myocar-
dium is expected, as noted in the relative values here.
Unlike gadofosveset, albumin concentration is
expected to remain consistent within an individual for
the image acquisition duration. Although there is some
within-subject variability (Fig. 4b), this is a representa-
tion of the imprecision in data acquisition and does not
correlate with time postbolus. The mean calculated albu-
min concentration in the left ventricle of the seven vol-
unteers was 0.07 mM (range, 0.04–0.08 mM); in the
myocardium the mean calculated Csa was 0.02 mM
(range, 0.01–0.03 mM).
A reference measure of albumin concentration was not
available for comparison. Serum albumin levels in plasma
(Csa_plasma) are expected to be approximately 3.5–5.0 g/dL
(0.52–0.74 mM) (53). Assuming a hematocrit (Hct) of 0.42,
this equates to albumin levels in whole blood of 0.30–0.43
mM (where blood concentration¼Csa_plasma (1Hct)).
Previous studies quote interstitial fluid albumin concen-
trations (Csa_interstitial) of 0.2–0.4 mM (10,11,54). However,
the myocardium ROI contains intravascular, extravascular
extracellular and intracellular spaces. Neglecting the intra-
cellular space, as gadofosveset cannot directly access it,
and assuming an extracellular volume fraction (EVF) of
0.25 (55), a myocardial blood volume (MBV) of 8% (56) and
a hematocrit in capillaries (Hctcap) of 0.25, tissue albumin
(Csa_tissue, measurable using gadofosveset) may be expected
to be in the range 0.07–0.11 mM (where Csa_tissue¼MBV.
(Csa_plasma.(1Hctcap))þCsa_interstitial. (EVFMBV)). This
range of expected values assumes that all blood vessels in
the myocardium are capillaries; in reality, a proportion
would be larger than capillaries and would, therefore, have
a higher Hct, leading to a slightly lower range of expected
Csa_tissue values.
Calculated Csa values were lower than might be
expected in healthy volunteers. Factors contributing to
an underestimation could include the relative timings of
the T1 and T2 measurements, the separation of gadofos-
veset delivery into a timing bolus and a main bolus, and
the potential incompatibility of translated in vitro relax-
ivities (for example, due to fundamental differences
between in vitro and in vivo measurement of relaxivity
(57), although the inclusion of albumin in the in vitro
samples used for relaxivity calculation will moderate
this issue). The selected scanning parameters were opti-
mized for myocardial tissue and are likely to lead to an
underestimation in DR2 in the left ventricle. The large
error bars on the Csa calculations in the left ventricle
(Fig. 4b) confirm the difficulty in applying the model to
left ventricular data acquired under conditions opti-
mized for myocardial measurement. Simulated data sug-
gest that underestimation in DR2 may result in a
substantial underestimation in calculated Csa. However,
it should be noted that the described method may not be
appropriate or necessary in the left ventricle as albumin
levels in blood can be readily measured from blood sam-
ples. The primary utility of the method may be in pro-
viding measurement of albumin concentration in tissue,
where Cg is lower and Csa is conventionally difficult to
acquire.
A previous study using the contrast agent gadobenate
(58), which has a much lower albumin binding affinity
than gadofosveset (59), suggested that renal protein leak-
age could be identified by analyzing tubular flow differ-
ences following injection of two contrast agents, one
binding and one nonbinding. Attempts have also been
made to map protein levels by utilizing the distinct field
dependency of the bound and free gadofosveset molecule
(termed delta relaxation enhanced MR, DREMR) (60,61),
although this approach requires the use of additional
hardware to modulate B0 field strength. The advantage of
the method described in this study over either of these
approaches is that it only requires a single contrast agent
injection and may be readily derived from routinely
acquired R1 and R2 measurements using conventional
equipment.
CONCLUSIONS
The model presented here demonstrates the feasibility of
determining in vitro serum albumin concentration using
pre- and postgadofosveset measurements of R1 and R2 at
high B0 fields. The method was successfully validated
using in vitro samples at 3.0T and 4.7T. Feasibility
assessment in a small number of human volunteers was
performed using cardiac images, and consistent DR1, DR2
and Cg values were determined. Underestimation of Csa
may be the result of several contributing factors, includ-
ing the timing of the image acquisitions and translation
of in vitro relaxivities. A more effective application of
this method may be in tumor angiogenesis, where
increased extravascular macromolecular leakage rates are
observed and imaging is less restricted by cardiac or
respiratory motion. Further in vivo assessment is sug-
gested, to include: simultaneous T1 and T2 measurement;
additionally acquiring images between the timing bolus
and the main bolus; and blood sampling to establish
hematocrit and reference blood albumin levels.
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This novel approach may enable noninvasive assess-
ment of extravascular leakage of albumin, utilizing
parameters acquired during routine imaging, in regions
where implementation of invasive techniques for mea-
surement of interstitial albumin is conventionally chal-
lenging. A range of potential clinical applications are
envisaged, including assessment of myocardial infarc-
tion, tumor angiogenesis, and response to treatment.
ACKNOWLEDGMENTS
This study was part-funded by a BBSRC industrial CASE
award, in partnership with AstraZeneca (BB/G017220/1).
The authors thank all volunteers taking part in this
study, and acknowledge the assistance of staff at North-
western Memorial Hospital, Chicago, Leeds Teaching
Hospitals NHS Trust and AstraZeneca, Alderley Park,
Cheshire. The authors are also grateful to Azhar Maq-
bool, Richard Gillot, and David Broadbent for assistance
with 3.0T in vitro data acquisition, Michael Markl at
Northwestern University, Chicago, for facilitating the
volunteer studies, and the National Institutes of Health
Research Project Grant (R01) for providing in vivo scan
time and salary support.
REFERENCES
1. Doweiko JP, Nompleggi DJ. Role of albumin in human physiology
and pathophysiology. J Parenter Enteral Nutr 1991;15:207–211.
2. Bhattacharya AA, Grune T, Curry S. Crystallographic analysis reveals
common modes of binding of medium and long-chain fatty acids to
human serum albumin. J Mol Biol 2000;303:721–732.
3. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. Predicting
plasma protein binding of drugs: a new approach. Biochem Pharma-
col 2002;64:1355–1374.
4. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in criti-
cal illness. Br J Anaesth 2000;85:599–610.
5. Bradley J, Cunningham K, Jackson V. Serum protein levels in crit-
ically ill surgical patients. Intensive Care 1981;7:291–295.
6. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albu-
min and risk of myocardial infarction and all-cause mortality in the
Framingham offspring study. Circulation 2002;106:2919–2924.
7. Ballmer PE. Causes and mechanisms of hypoalbuminaemia. Clin Nutr
2001;20:271–273.
8. Saeed M, Van Dijke CF, Mann JS, Wendland MF, Rosenau W,
Higgins CB, Brasch RC. Histologic confirmation of microvascular
hyperpermeability to macromolecular MR contrast medium in reper-
fused myocardial infarction. J Magn Reson Imaging 1998;8:561–567.
9. Seitz RJ, Wechsler W. Immunohistochemical demonstration of serum
proteins in human cerebral gliomas. Acta Neuropathol 1987;73:145–
152.
10. Poulsen HL. Subcutaneous interstitial fluid albumin concentration in
long-term diabetes-mellitus. Scand J Clin Lab Invest 1973;32:167–
173.
11. Haaverstad R, Romslo I, Larsen S. Protein concentration of subcuta-
neous interstitial fluid in the human leg. J Vasc Res 1996;16:111–117.
12. Ellmerer M, Schaupp L, Brunner GA, Sendlhofer G, Wutte A, Wach
P, Pieber TR. Measurement of interstitial albumin in human skeletal
muscle and adipose tissue by open-flow microperfusion. Am J Phys-
iol Endocrinol Metab 2000;278:E352–E356.
13. Waterton JC. Translational magnetic resonance imaging and spectros-
copy: opportunities and challenges. In: Garrido L, Beckmann N, edi-
tors. New applications of NMR in drug discovery and development.
Cambridge, UK: RSC press; 2013. p 333–360.
14. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau
W, Lu Y, Brasch RC. Correlation of dynamic contrast-enhanced MR
imaging with histologic tumor grade: comparison of macromolecular
and small-molecular contrast media. AJR Am J Roentgenol 1998;171:
941–949.
15. Roberts TPL, Turetschek K, Preda A, Novikov V, Moeglich M,
Shames DM, Brasch RC, Weinmann HJ. Tumor microvascular
changes to anti-angiogenic treatment assessed by MR contrast media
of different molecular weights. Acad Radiol 2002;9(Suppl. 2):S511–
S513.
16. Schwitter J, Saeed M, Wendland MF, Derugin N, Canet E, Brasch RC,
Higgins CB. Influence of severity of myocardial injury on distribution
of macromolecules: extravascular versus intravascular gadolinium-
based magnetic resonance contrast agents. J Am Coll Cardiol 1997;30:
1086–1094.
17. Aime S, Caravan P. Biodistribution of gadolinium-based contrast
agents, including gadolinium deposition. J Magn Reson Imaging
2009;30:1259–1267.
18. Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S,
McMurry TJ, Walovitch RC. MS-325: albumin-targeted contrast agent
for MR angiography. Radiology 1998;207:529–538.
19. Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular
MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol
2006;60:353–366.
20. Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool
contrast agents. Eur Radiol 2007;17:3017–3024.
21. Puig J, Blasco G, Essig M, et al. Albumin-binding MR blood pool con-
trast agent improves diagnostic performance in human brain tumour:
comparison of two contrast agents for glioblastoma. Eur Radiol 2012:
1–9.
22. Milot L, Haider M, Foster L, McGregor C, Law C. Gadofosveset triso-
dium in the investigation of focal liver lesions in noncirrhotic liver:
early experience. J Magn Reson Imaging 2012;36:738–742.
23. Thouet T, Schnackenburg B, Kokocinski T, Fleck E, Nagel E, Kelle S.
Visualization of chronic myocardial infarction using the intravascular
contrast agent MS-325 (Gadofosveset) in patients. Sci World J 2012:
1–6.
24. Phinikaridou A, Andia ME, Protti A, Indermuchle A, Shah A, Smith
A, Warley A, Botnar RM. Noninvasive magnetic resonance imaging
evaluation of endothelial permeability in murine atherosclerosis
using an albumin-binding contrast agent. Circulation 2012;126:707–
719.
25. Leporq B, Dumortier J, Pilleul F, Beuf O. 3D-liver perfusion MRI with
the MS-325 blood pool agent: A noninvasive protocol to asses liver
fibrosis. J Magn Reson Imaging 2012;35:1380–1387.
26. Richardson OC, Scott MLJ, Tanner SF, Waterton JC, Buckley DL.
Overcoming the low relaxivity of gadofosveset at high field with spin
locking. Magn Reson Med 2012;68:1234–1238.
27. Eldredge HB, Spiller M, Chasse JM, Greenwood MT, Caravan P. Spe-
cies dependence on plasma protein binding and relaxivity of the
gadolinium-based MRI contrast agent MS-325. Invest Radiol 2006;41:
229–243.
28. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of MS-
325 with human serum albumin and its effect on proton relaxation
rates. J Am Chem Soc 2002;124:3152–3162.
29. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H-J.
Comparison of magnetic properties of MRI contrast media solutions
at different magnetic field strengths. Invest Radiol 2005;40:715–724.
30. Muller RN, Raduchel B, Laurent S, Platzek J, Pierart C, Mareski P,
Vander Elst L. Physicochemical characterization of MS-325, a new
gadolinium complex, by multinuclear relaxometry. Eur J Inorg Chem
1999;1999:1949–1955.
31. Aime S, Fasano M, Terreno E, Botta M. Protein-bound metal chelates.
In: Merbach AE, Toth E, editors. The chemistry of contrast agents in
medical magnetic resonance imaging. Chichester: John Wiley & Sons;
2001. p 193–242.
32. Port M, Corot C, Violas X, Robert P, Raynal I, Gagneur G. How to
compare the efficiency of albumin-bound and nonalbumin-bound
contrast agents in vivo. Invest Radiol 2005;40:565–573.
33. Aime S, Chiaussa M, Digilio G, Gianolio E, Terreno E. Contrast agents
for magnetic resonance angiographic applications: 1H and 17O NMR
relaxometric investigations on two gadolinium(III) DTPA-like chelates
endowed with high binding affinity to human serum albumin. J Biol
Inorg Chem 1999;4:766–774.
34. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular
parameters and increasing magnetic field strength on relaxivity of
gadolinium- and manganese-based T1 contrast agents. Contrast Media
Mol Imaging 2009;4:89–100.
35. Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging
method for clinical MR. Magn Reson Med 1986;3:823–833.
252 Richardson et al.
36. Henkelman RM. Measurement of signal intensities in the presence of
noise in MR images. Med Phys 1985;12:232–233.
37. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan
MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI)
for high-resolution T1 mapping of the heart. Magn Reson Med 2004;
52:141–146.
38. Xue H, Shah S, Greiser A, Guetter C, Littmann A, Jolly M-P, Arai AE,
Zuehlsdorff S, Guehring J, Kellman P. Motion correction for myocar-
dial T1 mapping using image registration with synthetic image esti-
mation. Magn Reson Med 2012;67:1644–1655.
39. Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV,
Simonetti OP. T2 quantification for improved detection of myocardial
edema. J Cardiovasc Magn Reson 2009;11:56.
40. Wang Y, Spiller M, Caravan P. Evidence for weak protein binding of
commercial extracellular gadolinium contrast agents. Magn Reson
Med 2010;63:609–616.
41. Bagher-Ebadian H, Paudyal R, Nagaraja TN, Croxen RL,
Fenstermacher JD, Ewing JR. MRI estimation of gadolinium and albu-
min effects on water proton. Neuroimage 2011;54(Suppl. 1):S176–
S179.
42. Pedersen SF, Thrysoe SA, Paaske WP, Thim T, Falk E, Ringgaard S,
Kim WY. CMR Assessment of endothelial damage and angiogenesis
in porcine coronary arteries using gadofosveset. J Cardiovasc Magn
Reson 2011;13:10.
43. Biris O, Benefield B, Harris KR, Lee DC. A steady-state method for
computation of myocardial blood volume with the intravascular con-
trast agent Ablavar. J Cardiovasc Magn Reson 2012;14(Suppl. 1):P49.
44. Makowski MR, Wiethoff AJ, Uribe S, et al. Congenital heart disease:
Cardiovascular MR imaging by using an intravascular blood pool con-
trast agent. Radiology 2011;260:680–688.
45. Ritter CO, Wilke A, Wichmann T, Beer M, Hahn D, Kostler H. Com-
parison of intravascular and extracellular contrast media for absolute
quantification of myocardial rest-perfusion using high-resolution
MRI. J Magn Reson Imaging 2011;33:1047–1051.
46. Wagner M, Rosler R, Lembcke A, et al. Whole-heart coronary mag-
netic resonance angiography at 1.5 tesla: Does a blood-pool contrast
agent improve diagnostic accuracy? Invest Radiol 2011;46:152–159.
47. Noeske R, Seifert F, Rhein KH, Rinneberg H. Human cardiac imaging
at 3 T using phased array coils. Magn Reson Med 2000;44:978–982.
48. Zhao J, Clingman C, Narvainen M, Kauppinen R, van Zijl P. Oxygen-
ation and hematocrit dependence of transverse relaxation rates of
blood at 3T. Magn Reson Med 2007;58:592–597.
49. Zaman A, Higgins DM, Kouwenhoven M, Kidambi A, Greenwood JP,
Plein S. Robust myocardial T2 and T2* mapping at 3T. J Cardiovasc
Magn Reson 2012;14:(Suppl. 1):P306.
50. Stanisz GJ, Odrobina EE, Pun J, Escaravage M, Graham SJ, Bronskill
MJ, Henkelman RM. T1, T2 relaxation and magnetization transfer in
tissue at 3T. Magn Reson Med 2005;54:507–512.
51. Brasch RC. Rationale and applications for macromolecular Gd-based
contrast agents. Magn Reson Med 1991;22:282–287.
52. Bane O, Lee DC, Benefield B, Markl M, Carr J, Carroll TJ. A pilot
study of leakage and compartmentalization of the contrast agent
Ablavar. J Cardiovasc Magn Reson 2013;15(Suppl. 1):E7.
53. Rothschild M, Oratz M, Schreiber S. Albumin synthesis. N Engl J
Med 1972;286:748–757.
54. Fogh-Andersen N, Altura BM, Altura BT, Siggaardandersen O. Com-
position of interstitial fluid. Clin Chem 1995;41:1522–1525.
55. Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Druey
KM, Ugander M, Arai AE. Extracellular volume fraction mapping in
the myocardium, part 2: Initial clinical experience. J Cardiovasc
Magn Reson 2012;14:64.
56. Broadbent DA, Biglands JD, Larghat A, Sourbron SP, Radjenovic A,
Greenwood JP, Plein S, Buckley DL. Myocardial blood flow at rest
and stress measured with dynamic contrast-enhanced MRI: Compari-
son of a distributed parameter model with a Fermi function model.
Magn Reson Med 2013;70:1591–1597.
57. Pickup S, Wood AK, Kundel HL. Gadodiamide T1 relaxivity in brain
tissue in vivo is lower than in saline. Magn Reson Med 2005;53:35–
40.
58. Notohamiprodjo M, Pedersen M, Glaser C, Helck AD, Lodemann K-P,
Jespersen B, Fischereder M, Reiser MF, Sourbron SP. Comparison of
Gd-DTPA and Gd-BOPTA for studying renal perfusion and filtration.
J Magn Reson Imaging 2011;34:595–607.
59. Henrotte V, Vander Elst L, Laurent S, Muller RN. Comprehensive
investigation of the non-covalent binding of MRI contrast agents with
human serum albumin. J Biol Inorg Chem 2007;12:929–937.
60. Alford JK, Rutt BK, Scholl TJ, Handler WB, Chronik BA. Delta relaxa-
tion enhanced MR: Improving activation - specificity of molecular
probes through R1 dispersion imaging. Magn Reson Med 2009;61:
796–802.
61. Alford JK, Sorensen AG, Benner T, Chronik AB, Handler BW, Scholl
JT, Madan G, Caravan P. Direct protein imaging of inflammation in
the human hand. In Proceedings of the 19th Annual Meeting of
ISMRM, Montreal, Canada, 2011. Abstract 452.
Biomarker of Tissue Albumin Concentration 253
